杨瑾,莫国栋,卢志军,翁舜龙,李嘉良
YANG Jin,MO Guodong,LU Zhijun,WENG Shunlong,LI Jialiang

• 1:中山市第二人民医院药剂科

摘要(Abstract)：

目的回顾性分析我院干扰素注射液引起的不良反应(ADR)发生的特点,为我院临床安全合理用药提供依据。方法对我院2013年~2016年107例干扰素注射液ADR报告进行分析。结果 107例ADR中,男性患者居多,占67.29%。20~50 a年龄段患者占92.52%。不良反应主要累及血液系统,有64例,占56.64%。经过相应治疗后患者均转归良好。结论医务人员应在充分了解干扰素注射液的基础上,继续加强我院ADR的报告及监测工作,以减少或避免不良反应发生。
OBJECTIVE To retrospectively analyze the characteristics of the adverse drug reactions( ADR) caused by interferon injection,and to provide reference for the clinical application of drugs. METHODS 107 reports of interferon injection ADR collected by our hospital in the period of 2013-2016 were analyzed including patients' age,sex and names,types of ADRs,the organs,clinical manifestations and outcomes,relevance evaluations. RESULTS In 107 ADR cases,the male patients were 67.29%,more than female patients. The patients accounted for 92.52% at twenty to fifty years old. Adverse reactions with 64 cases( 56.64%) mainly involving the blood system. After corresponding treatment,patients had good outcome. CONCLUSION Medical staff should be aware ADRs of interferon injection,and monitoring and reporting of ADR should be strengthened to reduce and prevent the occurrence of ADR.

关键词(KeyWords)： 干扰素注射液;药物不良反应;合理用药;回顾分析;监测
interferon injection;ADR;reasonable drug use;retrospective analysis;monitor

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 杨瑾,莫国栋,卢志军,翁舜龙,李嘉良
YANG Jin,MO Guodong,LU Zhijun,WENG Shunlong,LI Jialiang

参考文献(References)：

• [1]曲彩虹.长效干扰素α治疗176例慢性病毒性肝炎的不良反应分析[J].中国医院药学杂志,2015,35(12):1116-1118.
• [2]杨燕妮.加替沙星不良反应/事件报告分析[J].今日药学,2014,24(4):293-295.
• [3]郭涛.干扰素治疗慢性肝炎诱发癫痫发作1例[J].现代中西医结合杂志,2010,19(18):2333
• [4]王宁,赵子龙.干扰素治疗慢性乙型肝炎期间发生闭经1例[J].中国医药导刊,2012,12(12):2139.
• [5]雷招宝.药物不良反应中的性别差异[J].药物不良反应杂志,2010,2(3):177-179.
• [6]张玉秋等,99例干扰素的不良反应分析[J].药物不良反应杂志,2013,5(3):308-311.
• [7]Taketomo C K.Hodding J K,Kraus D M.Pediatric Dosage Handbook[M].7th Edition.Ohio:Hudson,2000-2001:524.
• [8]Ronald Arky.Physicians’Desk Reference[M].53 Edition.Montvale:Medical Economics Company,1999:2699.
• [9]杜亚明.3种方案治疗慢性乙肝的经济学分析[J].中国药房,2008.19(29):2247-2249.
• [10]杨剑辉.恩替卡韦和拉米夫定治疗慢性乙型肝炎的Meta分析[J].今日药学,2014,24(4):276-283.
• [11]EASL.International Consensus Conference on Hepatitis B[J].J Hepatol,2013,13(11):1787-1793.
• [12]Ong S C,Lim S G,Li S C.How big is the financial burden of hepatitis B to society A cost-of-illness study of hepatitis B infection in Singapore[J].Journal of Viral Hepatitis,2009,16(1),53-63.
• [13]杨剑辉.恩替卡韦和拉米夫定治疗慢性乙型肝炎的Meta分析[J].今日药学,2014,24(4):276-283.
• [14]Rauw J,Ahmed S,Petrella T.Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma[J].Med Oncol,2012,29(2):1304-1307.
• [15]Popescu C,Arama V,Gliga S.Acute pericarditis due to pegylated interferon alpha therapy for chronic HCV hepatitis-case report[J].BMC Gastroenterol,2011,11(1):30.
• [16]Slavenburg S,Heijdra Y F,Drenth J P.Pneumonitis as a consequence of interferon-ribavirin combination therapy for hepatitis C:a review of the literature[J].Dig Dis Sci,2010,55(3):579-585.
• [17]Huang Y X,Chen X Y,Ma L N,et al.Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin[J].Zhonghua Gan Zang Bing Za Zhi,2012,20(3):216-220.
• [18]范春蕾,张鑫.聚乙二醇干扰素α-2b致低钾血症合并甲状腺功能减退症[J].药物不良反应杂志,2008,10(4):286-287.